Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII

Yuko Kamata, Torayuki Okuyama, Motomichi Kosuga, Aya O'hira, Arihiko Kanaji, Kyoko Sasaki, Masao Yamada, Noriyuki Azuma

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Recent advances in systemic treatments for mucopolysaccharidosis have led to therapies that improve the multiple somatic features of this disease, but the therapeutic effect on ocular manifestations such as corneal clouding is not satisfactory. Here, we administered an adenovirus expressing human β-glucuronidase (AxCAhGUS) into the anterior chamber or intrastromal region of the cornea in mice with mucopolysaccharidosis type VII (B6/MPSVII), and successfully treated corneal clouding of MPSVII. When we injected AxCAhGUS into the anterior chamber of the eyes, cells expressing β-glucuronidase (GUSB) were located mainly in the trabecular meshwork as well as in all corneal regions, and subsequent pathological corrections in the cornea were achieved. Widespread transgene expression was also observed when we administered AxCAhGUS inside the cornea after lamellar keratotomy, and rapid elimination of the lysosomal storage in the corneal keratocytes occurred. Furthermore, intrastromal vector administration did not generate significant levels of anti-adenovirus neutralizing antibodies, and secondary vector administration was effective. Based on these observations, we conclude that it is worth developing a treatment strategy for corneal clouding in mucopolysaccharidosis based on direct intraocular administration of adenoviral vectors.

Original languageEnglish
Pages (from-to)307-312
Number of pages6
JournalMolecular Therapy
Volume4
Issue number4
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Mucopolysaccharidosis VII
Adenoviridae
Genetic Therapy
Cornea
Mucopolysaccharidoses
Glucuronidase
Anterior Chamber
Eye Manifestations
Corneal Keratocytes
Trabecular Meshwork
Human Adenoviruses
Therapeutic Uses
Neutralizing Antibodies
Transgenes
Therapeutics

Keywords

  • Adenovirus
  • Corneal clouding
  • Mucopolysaccharidosis

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII. / Kamata, Yuko; Okuyama, Torayuki; Kosuga, Motomichi; O'hira, Aya; Kanaji, Arihiko; Sasaki, Kyoko; Yamada, Masao; Azuma, Noriyuki.

In: Molecular Therapy, Vol. 4, No. 4, 2001, p. 307-312.

Research output: Contribution to journalArticle

Kamata, Y, Okuyama, T, Kosuga, M, O'hira, A, Kanaji, A, Sasaki, K, Yamada, M & Azuma, N 2001, 'Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII', Molecular Therapy, vol. 4, no. 4, pp. 307-312. https://doi.org/10.1006/mthe.2001.0461
Kamata, Yuko ; Okuyama, Torayuki ; Kosuga, Motomichi ; O'hira, Aya ; Kanaji, Arihiko ; Sasaki, Kyoko ; Yamada, Masao ; Azuma, Noriyuki. / Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII. In: Molecular Therapy. 2001 ; Vol. 4, No. 4. pp. 307-312.
@article{0c553a3158b145fab8e98b7762f9ca1f,
title = "Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII",
abstract = "Recent advances in systemic treatments for mucopolysaccharidosis have led to therapies that improve the multiple somatic features of this disease, but the therapeutic effect on ocular manifestations such as corneal clouding is not satisfactory. Here, we administered an adenovirus expressing human β-glucuronidase (AxCAhGUS) into the anterior chamber or intrastromal region of the cornea in mice with mucopolysaccharidosis type VII (B6/MPSVII), and successfully treated corneal clouding of MPSVII. When we injected AxCAhGUS into the anterior chamber of the eyes, cells expressing β-glucuronidase (GUSB) were located mainly in the trabecular meshwork as well as in all corneal regions, and subsequent pathological corrections in the cornea were achieved. Widespread transgene expression was also observed when we administered AxCAhGUS inside the cornea after lamellar keratotomy, and rapid elimination of the lysosomal storage in the corneal keratocytes occurred. Furthermore, intrastromal vector administration did not generate significant levels of anti-adenovirus neutralizing antibodies, and secondary vector administration was effective. Based on these observations, we conclude that it is worth developing a treatment strategy for corneal clouding in mucopolysaccharidosis based on direct intraocular administration of adenoviral vectors.",
keywords = "Adenovirus, Corneal clouding, Mucopolysaccharidosis",
author = "Yuko Kamata and Torayuki Okuyama and Motomichi Kosuga and Aya O'hira and Arihiko Kanaji and Kyoko Sasaki and Masao Yamada and Noriyuki Azuma",
year = "2001",
doi = "10.1006/mthe.2001.0461",
language = "English",
volume = "4",
pages = "307--312",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII

AU - Kamata, Yuko

AU - Okuyama, Torayuki

AU - Kosuga, Motomichi

AU - O'hira, Aya

AU - Kanaji, Arihiko

AU - Sasaki, Kyoko

AU - Yamada, Masao

AU - Azuma, Noriyuki

PY - 2001

Y1 - 2001

N2 - Recent advances in systemic treatments for mucopolysaccharidosis have led to therapies that improve the multiple somatic features of this disease, but the therapeutic effect on ocular manifestations such as corneal clouding is not satisfactory. Here, we administered an adenovirus expressing human β-glucuronidase (AxCAhGUS) into the anterior chamber or intrastromal region of the cornea in mice with mucopolysaccharidosis type VII (B6/MPSVII), and successfully treated corneal clouding of MPSVII. When we injected AxCAhGUS into the anterior chamber of the eyes, cells expressing β-glucuronidase (GUSB) were located mainly in the trabecular meshwork as well as in all corneal regions, and subsequent pathological corrections in the cornea were achieved. Widespread transgene expression was also observed when we administered AxCAhGUS inside the cornea after lamellar keratotomy, and rapid elimination of the lysosomal storage in the corneal keratocytes occurred. Furthermore, intrastromal vector administration did not generate significant levels of anti-adenovirus neutralizing antibodies, and secondary vector administration was effective. Based on these observations, we conclude that it is worth developing a treatment strategy for corneal clouding in mucopolysaccharidosis based on direct intraocular administration of adenoviral vectors.

AB - Recent advances in systemic treatments for mucopolysaccharidosis have led to therapies that improve the multiple somatic features of this disease, but the therapeutic effect on ocular manifestations such as corneal clouding is not satisfactory. Here, we administered an adenovirus expressing human β-glucuronidase (AxCAhGUS) into the anterior chamber or intrastromal region of the cornea in mice with mucopolysaccharidosis type VII (B6/MPSVII), and successfully treated corneal clouding of MPSVII. When we injected AxCAhGUS into the anterior chamber of the eyes, cells expressing β-glucuronidase (GUSB) were located mainly in the trabecular meshwork as well as in all corneal regions, and subsequent pathological corrections in the cornea were achieved. Widespread transgene expression was also observed when we administered AxCAhGUS inside the cornea after lamellar keratotomy, and rapid elimination of the lysosomal storage in the corneal keratocytes occurred. Furthermore, intrastromal vector administration did not generate significant levels of anti-adenovirus neutralizing antibodies, and secondary vector administration was effective. Based on these observations, we conclude that it is worth developing a treatment strategy for corneal clouding in mucopolysaccharidosis based on direct intraocular administration of adenoviral vectors.

KW - Adenovirus

KW - Corneal clouding

KW - Mucopolysaccharidosis

UR - http://www.scopus.com/inward/record.url?scp=0034756448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034756448&partnerID=8YFLogxK

U2 - 10.1006/mthe.2001.0461

DO - 10.1006/mthe.2001.0461

M3 - Article

VL - 4

SP - 307

EP - 312

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 4

ER -